MedTrace Logo

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

NCT00004208 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2015-03-11

No results posted yet for this study

Summary

The main objective of this trial is to evaluate the efficacy and toxicity of intensive immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion dependent low and intermediate risk myelodysplastic syndrome (MDS).

Conditions

Interventions

DRUG

ATG + CSA

Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)

BEHAVIORAL

Supportive care

Patients randomized to this arm will be treated as outpatients.

Sponsors & Collaborators

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Jakob R. Passweg, MS · Kantonsspital Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Primary Completion
2006-10-31
Completion
2011-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004208 on ClinicalTrials.gov